Vanderbilt University — VIPER Microfluidic Control System¶
Tissue-chips-in-space automated perfusion platform — TRL stagnation but PI is a serial innovator
Investigated: Session 99, 2026-04-07
Institution & Team¶
| Field | Value |
|---|---|
| Lead Org | Vanderbilt University — Nashville, TN |
| PI | John P. Wikswo (University Distinguished Professor; founding Director, VIIBRE) |
| Co-I | Peter Alexander |
| States | PA, TN |
| Domain | Microfluidic organ-on-chip platforms for space biology |
John Wikswo is a major figure: - Founded VIIBRE (Vanderbilt Institute for Integrative Biosystems Research and Education) in 2001 - 76 invention disclosures, 47 issued patents - 2× R&D 100 Awards (1984 Neuromagnetic Current Probe, 2017 MultiWell MicroFormulator) - Named 2025 Vanderbilt Master Innovator (Nov 2025) - Licenses to Kiyatec Inc. and CN Bio Innovations (UK) - AIMBE College of Fellows (COF-1080) - Currently founding Regemus Technologies — startup to license/commercialize automated microfluidic perfusion systems for biomanufacturing optimization
FO Project¶
106604 — VIPER: Automated Microfluidic Pump-and-Valve for Tissue-Chips-In-Space¶
- Status: Completed, Closed Out Sep 2025
- TRL: 4 → 4 (began 4, current 4, target 6) — DID NOT ADVANCE
- TX: TX06.4.1 Air, Water, Microbial, and Acoustic Sensors
- Destination: Moon and Cislunar
- Period: Oct 2019 – Apr 2025 (5.5 years)
- Views: 1,212
Technology: VIPER (name shared with the lunar rover — unrelated) is a miniature pump-and-valve system with multiple small fluid reservoirs that automates complex biological and chemical mixing experiments in microgravity. Uses time-division fluidic multiplexing that mimics circadian/diurnal rhythms for tissue-chip perfusion. Designed to overcome limitations of current syringe-based ISS fluid handling devices.
Result: TRL stayed at 4 after 5.5 years. This is a notable failure to advance — the target was TRL 6. No ISS deployment found. No library items (documents) attached to the TechPort record.
TechPort Footprint¶
| Project | Program | Role | Period |
|---|---|---|---|
| 106604 | FO | Lead | 2019–2025 |
Single FO project. Wikswo's broader Vanderbilt portfolio is vast but not in TechPort (DARPA, NIH, DOE funded).
Funding¶
No USASpending contracts found specifically for this FO project or VIPER microfluidics under Vanderbilt. FO funding was likely via cooperative agreement.
Why TRL Didn't Advance¶
The 5.5-year project spanned the COVID period (2019-2025), which likely disrupted parabolic flight access. But the deeper issue may be that the FO project was a small piece of Wikswo's much larger microfluidics research program: - The VIPER platform is one component of the broader CAPCAS (Continuous Automated Perfusion Culture Analysis Systems) framework - Wikswo's lab simultaneously pursued DARPA/NIH organ-on-chip funding at much larger scale - The FO project may have been deprioritized relative to higher-dollar, higher-impact terrestrial programs - No ISS deployment = no operational environment test = TRL stuck at 4
Downstream Analysis¶
Direct FO Impact: Minimal¶
The VIPER FO project itself produced no visible downstream outcome. No publications found citing the FO project specifically. No ISS deployment. TRL didn't advance.
Indirect Impact via Wikswo's Portfolio: Significant¶
The microfluidic perfusion technology from Wikswo's lab (including VIPER concepts) is being commercialized through: 1. Regemus Technologies (startup in formation, 2025-2026) — licensing Vanderbilt's automated microfluidic perfusion portfolio for biomanufacturing optimization and living systems dynamics 2. CN Bio Innovations (UK) — existing licensee of Wikswo's organ-on-chip technology 3. Kiyatec Inc. — another existing licensee 4. Vanderbilt Innovation Catalyst Fund (2025-2026, $59,990) — "Accelerating the development and commercialization of a robot scientist self-driving biological laboratory"
The pattern: FO was a minor funding source in a massive research portfolio. The technology matured through other channels (DARPA MicroPhysiological Systems, NIH NCATS Tissue Chips), and FO's contribution is essentially invisible in the outcome chain.
Assessment¶
| Dimension | Rating |
|---|---|
| Technology readiness | Low for FO-specific project (TRL 4→4) |
| PI research impact | Very high (47 patents, 2 R&D 100 Awards, multiple spinouts) |
| Commercial viability | Active — Regemus Technologies forming |
| Downstream from FO | Negligible — FO was minor contributor to large portfolio |
| Confidence | Confirmed (TRL stagnation); Suggestive (Regemus connection to FO concepts) |
Outcome category: TRL Stagnation — FO Minor in Large Portfolio
Archetype: Senior academic PI with massive portfolio uses FO as minor funding source. Technology matures through bigger programs (DARPA, NIH). FO contribution is real but invisible — the flight test was one data point in a 20-year research arc.
Time dimension: FO project ran 2019-2025 (5.5 years). Wikswo's microfluidics work started ~2001. Regemus Technologies forming 2025-2026. FO was a brief detour in a much longer trajectory.
Open Questions¶
- Was a parabolic flight actually conducted? No flight data or reports found.
- Does Regemus Technologies incorporate any FO-specific results?
- What caused the TRL stagnation — COVID, deprioritization, or technical failure?
- Will Tissue-Chips-In-Space programs (NIH/NCATS) use VIPER-derived technology on ISS?
Sources: TechPort 106604; Vanderbilt News (2025 Master Innovators, Nov 2025); VIIBRE website; Vanderbilt Innovation Catalyst Fund; AIMBE